Ampio Pharmaceuticals to Participate in the Alliance Global Partners' Virtual Summer Healthcare Symposium
Ampio Pharmaceuticals (NYSE American: AMPE) will participate in one-on-one meetings with institutional investors at the Alliance Global Partners' Virtual Summer Healthcare Symposium on June 17, 2021. This event is by invitation only, and no webcast will be available. Ampio focuses on immunology-based therapies for inflammatory conditions, with its lead drug Ampion™ backed by a strong patent portfolio, ensuring market exclusivity until 2035 upon FDA approval. The company emphasizes its commitment to advancing treatment options amid growing clinical demand.
- None.
- None.
ENGLEWOOD, Colo., June 11, 2021 /PRNewswire/ -- Ampio Pharmaceuticals (NYSE American: AMPE), a clinical stage biopharmaceutical company focused on the advancement of immunology-based therapies for prevalent inflammatory conditions, today announced that management will participate in a series of one-on-one meetings with institutional investors throughout the day at the Alliance Global Partners' Virtual Summer Healthcare Symposium on June 17, 2021.
Due to the invitation-only format of the event, no webcast will be available.
About Ampio Pharmaceuticals
Ampio Pharmaceuticals, Inc. is a biopharmaceutical company primarily focused on the advancement of immunology-based therapies to treat prevalent inflammatory conditions for which there are limited treatment options. Ampio's lead drug, Ampion™, is backed by an extensive patent portfolio with intellectual property protection extending through 2035 and will be eligible for 12-year FDA market exclusivity upon approval as a novel biologic under the biologics price competition and innovation act (BPCIA).
Forward Looking Statements
Ampio's statements in this press release that are not historical fact, and that relate to future plans or events, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by the use of words such as "believe," "expect," "plan," "anticipate," and similar expressions. These forward-looking statements include statements regarding Ampio's expectations with respect to Ampion and its classification, as well as those associated with regulatory approvals and other FDA decisions, the Biological License Application ("BLA"), the ability of Ampio to enter into partnering arrangements, clinical trials and decisions and changes in business conditions and similar events, the ability to receive regulatory approval to conduct clinical trials, that Ampion may be used to treat ARDS induced by COVID-19, all of which are inherently subject to various risks and uncertainties. The risks and uncertainties involved include those detailed from time to time in Ampio's filings with the Securities and Exchange Commission, including without limitation, under Ampio's Annual Report on Form 10-K and other documents filed with the Securities and Exchange Commission. Ampio undertakes no obligation to revise or update these forward-looking statements, whether as a result of new information, future events or otherwise.
Media Contact
Katie Kennedy
katie@gregoryfca.com
610-731-1045
View original content to download multimedia:http://www.prnewswire.com/news-releases/ampio-pharmaceuticals-to-participate-in-the-alliance-global-partners-virtual-summer-healthcare-symposium-301310483.html
SOURCE Ampio Pharmaceuticals, Inc.
FAQ
What is Ampio Pharmaceuticals' participation in the June 2021 healthcare symposium?
When is the Alliance Global Partners' Virtual Summer Healthcare Symposium?
What is the main focus of Ampio Pharmaceuticals?
What is Ampion and what potential does it have?
Will there be a webcast available for the healthcare symposium?
